Changing the future of Oncology.

Patient Resources 

Sutro’s Commitment to Patients

Cancer has been an unbeatable enemy for too long and for too many people. Advancing cancer treatments, giving patients longer lives and improving their quality of life remains the mission of Sutro Biopharma. By leveraging Sutro’s pioneering technology, we aim to rewrite the future of oncology.

This year alone, more than 1.8 million Americans will receive a cancer diagnosis, and sadly, more than 600,000 will die from the disease.[1]

Sutro and our employees are dedicated to improving survival and quality of life for cancer patients through our innovative research, discovery, development and manufacturing of novel cancer therapeutics.

We believe that Sutro’s revolutionary technology has the potential to change the future of oncology therapeutics; the Sutro team is purposeful in its quest to fully realize the potential of its technology. Sutro is uniquely positioned to chart a path that allows its technology to fully intervene in human disease in a way that no technology previously has. Together with its partners and investors, Sutro is discovering, developing and manufacturing important new therapeutics with a greater precision and a deeper understanding.

 

[1] American Cancer Society. Cancer Facts & Figures 2020. Accessed May 2020.

The fight against cancer is in all too familiar. The potential effectiveness and precision of Sutro’s clinical candidates may change the way patients battle cancer. The advancements Sutro has made with our CellFree technology and the ability to manufacture with rigorous GMP standards, is advancing treatment options for patients.

Clinical Trials

Sutro is currently advancing two wholly owned clinical-stage programs designed to provide patient benefit across multiple areas of unmet need.

 

STRO-001-BM1 is a CD74 Targeting antibody drug conjugate (ADC) for the potential treatment of multiple myeloma and NHL

  • STRO-001-BCM1 is an ongoing first-in-human, phase 1, open-label, multicenter, dose escalation study evaluating the safety, tolerability and preliminary anti-tumor activity of STRO-001-BM1 in adults with B-cell malignancies (NHL and multiple myeloma)

STRO-001-BM1 is a novel homogeneous ADC using precisely positioned non-natural amino acids

  • STRO-001-BM1 targets the tumor cell carrying two cytotoxins, these are non-cleavable maytansinoid linker-warheads (DAR=2) that are stable in circulation
  • The active warhead is internalized by the tumor cells, efficiently killing them while minimizing damage to surrounding healthy cells.

 

STRO–001-BM1 has received Orphan Drug designation for Multiple Myeloma patients.

 

For more information about this trial, visit www.clinicaltrials.gov

 

STRO-002-GM1 is a FolRa targeting ADC for the potential treatment of ovarian and endometrial cancer

  • STRO-002-GM1 is currently in an ongoing first-in-human, phase 1, open-label, multicenter, dose expansion study evaluating the safety, tolerability and preliminary anti-tumor activity of STRO-002-GM1 in adults with ovarian cancer

 

STRO-002-GM1 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids

  • STRO-002-GM1 targets the tumor cell carrying four cytotoxins, these are proprietary cleavable hemiasterlin linker-warheads (DAR=4) that are stable in circulation
  • The active warhead is internalized by the tumor cell, efficiently killing them in a manner that can stimulate the immune system, an effect called immunogenic cell death.[1]

    [1]Source: June 22, 2020 AACR 2020 Virtual Meeting II – Abstract 

 

For more information about this trial, visit www.clinicaltrials.gov

 

Background

Generation of the CD74 Targeting Antibody and a Novel, Specific, and Homogenous ADC, STRO-001[1]

Using a cell-free expression system, the non-natural amino acid pAMF was incorporated at 2 sites on an antibody that targets CD74. Optimal sites were selected based on conjugation efficiency, cell-killing activity and pharmacokinetics in mice. The cytotoxic non-cleavable maytansinoid linker-warheads are conjugated at the two pAMF sites on the CD74 targeting antibody to generate the ADC STRO-001-BM1.

[1] Zimmerman ES, et al. Bioconjug Chem2014;255(2);351-361.

Benefits

Sutro’s technology enables us to design and test complex molecules as potential next generation cancer treatments in a rapid cycle of weeks rather than months. This approach to discovery, without the cell, also transcends the limitations of biologics manufacturing.

Sutro has the world’s only cGMP cell-free manufacturing facility. This state-of-the-art facility, located in San Carlos, California, confers an important competitive advantage in entering clinical development following discovery and pre-clinical assessment of lead development candidate compounds. Currently, Sutro has two wholly owned clinical phase products manufactured in our cGMP facility, STRO-001-BM1 for the intended treatment of multiple myeloma and lymphoma and STRO-002-GM1 for the intended treatment of ovarian and endometrial cancers.

Thank You

Our Sutro team would like to express our heart-felt thanks to the patients, their families and health care providers for participating in our clinical studies.